Cellectis S.A.
NASDAQ: CLLS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andre Choulika
- Employees
- 216
- Headquarters
- Paris, France
- IPO year
- 2015
- Market cap
- $280.2M
- Website
- https://www.cellectis.com
Loading CLLS…
Loading profile data…Frequently asked questions about CLLS
What does Cellectis S.A. (CLLS) do?
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions...
Where does CLLS trade?
Cellectis S.A. (CLLS) trades on the NASDAQ Global Market.
What sector is CLLS in?
Cellectis S.A. (CLLS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cellectis S.A.?
Andre Choulika is the chief executive officer of Cellectis S.A. (CLLS).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in France.
Does CLLS pay a dividend?
Cellectis S.A. (CLLS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLLS go public?
Cellectis S.A. (CLLS) completed its initial public offering in 2015.
Is CLLS an ADR?
Yes — CLLS is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Cellectis S.A. reporting and dividends follow the underlying issuer.